<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High-level microsatellite-unstable (MSI-H) colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) represent a distinct subtype of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> commonly characterized by dense infiltration with cytotoxic T cells, most likely due to expression of MSI-H-related frameshift <z:chebi fb="7" ids="16670">peptides</z:chebi> (FSP) </plain></SENT>
<SENT sid="1" pm="."><plain>The contribution of FSP and classical antigens like MUC1 and CEA to the cellular immune response against MSI-H <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> had not been analyzed so far </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating and peripheral T cells from MSI-H (n = 4 and n = 14, respectively) and microsatellite-stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> patients (n = 26 and n = 17) using interferon gamma ELISpot assays </plain></SENT>
<SENT sid="3" pm="."><plain>Responses against 4 FSP antigens and <z:chebi fb="7" ids="16670">peptides</z:chebi> derived from MUC1 to CEA were compared with and without <z:mpath ids='MPATH_63'>depletion</z:mpath> of regulatory T cells, and the results were related to the presence of the respective antigens in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue </plain></SENT>
<SENT sid="4" pm="."><plain>Preexisting FSP-specific T cell responses were detected in <z:hpo ids='HP_0000001'>all</z:hpo> (4 out of 4) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating and in the majority (10 out of 14) of peripheral T cell samples from MSI-H <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, but rarely observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Preexisting T cell responses in MSI-H <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients were significantly more frequently directed against FSP tested in the present study than against <z:chebi fb="7" ids="16670">peptides</z:chebi> derived from classical antigens MUC1 or CEA (p = 0.049) </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_63'>Depletion</z:mpath> of regulatory T cells increased the frequency of effector T cell responses specific for MUC1/CEA-derived <z:chebi fb="7" ids="16670">peptides</z:chebi> and, to a lesser extent, T cell responses specific for FSP </plain></SENT>
<SENT sid="7" pm="."><plain>Our data suggest that the analyzed FSP may represent an immunologically relevant pool of antigens capable of eliciting antitumoral effector T cell responses </plain></SENT>
</text></document>